Amendments to the Claims:

The listing of claims below will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) 1-Aziridino-1-hydroxyiminomethyl derivatives with of the general formula I

$$R \xrightarrow{N-OH} R_1 \\ R_2 \\ R_2 \\ n$$

wherein

I

R stands for any organic residue that is able to bond is selected from the group consisting of a single bond and a linker moiety capable of bonding covalently two aziridine oxime groups,

 R_1 and R_2 independently of one another stand for a hydrogen atom or a are selected from the group consisting of -H₁, -CH₃, -C₂H₅, -CN, -COOH₃, -COOC₂H₅, -CONH₂, or -C₆H₅ group, provided that R_1 and R_2 are not both -H and provided that R_1 is not -H if R_2 is -CH₃ and R_1 is not -CH₃ if R_2 is -H₄, and

n is the whole number 2.

2. (Currently amended) 1-Aziridino-1-hydroxyiminomethyl-derivatives pursuant to The compound of claim 1, characterized by the fact that wherein R is any organic residue that is a linker moiety that is a divalent radical, derived from a molecule, selected from a single bond, the group consisting of linear or branched, saturated or unsaturated alkanes or heteroalkanes with up to 6 carbon atoms, and with up to four hetero atoms, and C₃-C₈ cycloalkanes that are optionally

substituted with short-chain C₁-C₆ alkyl, C₁-C₆ alkoxy, nitro, amino, monosubstituted amino, and/or halogen groups,

heterocyclic compounds with 3 to 6 ring atoms and up to four hetero atoms,

aromatic compounds with up to 8 ring atoms that are optionally substituted with eyano, hydroxy, short-chain C_t - C_6 -alkyl, C_t - C_6 -alkoxy, nitro, amino, monosubstituted amino, trihaloalkyl, and/or halogen groups, and

heteroaryls with 3 to 7 ring atoms and up to four hetero atoms.

- 3. (Currently amended) 1-Aziridino-1-hydroxyiminomethyl derivatives pursuant to The compound of claim 2, characterized by the fact that the parent substance wherein R is a linker moiety that is a divalent radical, derived from a molecule, selected from a single bond, methyl, the group consisting of methane, ethane, ethene, ethyne, propane, isopropane, butane, isobutane, see-butane, pentane, isopentane, neopentane, hexane, azine, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, pyrrole, pyrroline, pyrrolidine, imidazole, imidazoline, pyrazolidine, thiazole, thiazoline, thiazolidine, isothiazole, isothiazoline, isothiazolidine, benzothiazole, furan, dihydrofuran, tetrahydrofuran, benzofuran, thiophene, benzothiophene, oxazole, oxazoline, oxazolidine, benzoxazole, isoxazole, isoxazoline, isoxazolidine, piperidine, piperazine, pyrimidine, morpholine, dihydropyran, tetrahydropyran, pyridazine, benzene, furoxane, imidazole, imidazoline, imidazolidine, pyrazole, pyrazoline, pyrazolidine, pyridine and its pyridine N-oxide, dihydropyridine, pyrimidine, or pyrazine.
- 4. (Currently amended) 1-Aziridine-1-hydroxyiminomethyl derivatives pursuant to The compound of claim 1, characterized by the fact that wherein R₁ and R₂ independently of one another

represent hydrogen atoms or a are selected from the group consisting of -H and -CONH₂, group provided that R_1 and R_2 are not both -H.

- 5. (Currently amended) 1-Aziridino-1-hydroxyiminomethyl derivatives pursuant to The compound of claim 1, namely selected from the group consisting of
- 2,6-bis(1-aziridino-1-hydroxyiminomethyl)pyridine (6),
- 1,4-bis(1-aziridino-1-hydroxyiminomethyl)benzene (7),
- $1,4-di(\alpha-2-carbomoylaziridino-\alpha-hydroxyiminomethyl)$ benzene (8) $1,4-di(\alpha-2-carbamoylaziridino-\alpha-hydroxyiminomethyl)$ benzene,
- 1,3-bis(1-aziridino-1-hydroxyiminomethyl)benzene (2),
- 1,3,5-tris(1-aziridino-1-hydroxyiminomethyl)benzene (10),
- 1,3-di(α -2-carbamoylaziridino- α -hydroxyiminomethyl)benzene (11),
- 2,6-di(α -2-carbamoylaziridino- α -hydroxyiminomethyl)pyridine $\frac{(12)}{(12)}$,
- 3,5-bis(1-aziridino-1-hydroxyiminomethyl)pyridine (13),
- 2,5-bis(1-aziridino-1-hydroxyiminomethyl)pyridine (14),
- 2,4-bis(1-aziridino-1-hydroxyiminomethyl)pyridine (15),
- 2,5-bis(1-aziridino-1-hydroxyiminomethyl)furan (16),
- 3,4-bis[(aziridinyl)-1-hydroxyiminomethyl]furoxane (17),
- bis(2-methoxycarbonylaziridino)glyoxime (18),
- bis(2-carbamoylaziridino)glyoxime (19),
- 2,2'-azinobis(1-aziridino-1-hydroxyiminomethyl)propane (20), and
- 2,2'-azinobis[1-(2-carbamoylaziridino)-1-hydroxyimino]propane (21).

 Claims 6-8 (Canceled).

- 9. (Currently amended) Use of the 1-aziridino-1-hydroxymethyl derivatives pursuant to A method of treating tumors or cancerous diseases in humans which comprises administering to a human patient in need of treatment a therapeutically effective amount of a compound of claim 1-for the treatment of tumors or cancerous diseases.
- 10. (Currently amended) Use of The method of claim 9 wherein said compound is 1,1'-[1,2-bis(hydroxyimino)-1,2-ethanediyl]bisaziridine for the preparation of drugs for the treatment of tumors or cancerous diseases.

Claim 11 (Canceled).

- 12. (New) The compound of claim 2 wherein said C₃-C₈ cycloalkanes are substituted with at least one substituent selected from the group consisting of lower C₁-C₆ alkyl, lower C₁-C₆ alkoxy, nitro, amino, monosubstituted amino, and halogen groups.
- 13. (New) The compound of claim 2 wherein said aromatic compounds with up to 8 ring atoms are substituted with at least one substituent selected from the group consisting of cyano, hydroxy, lower C₁-C₆ alkyl, lower C₁-C₆ alkoxy, nitro, amino, monosubstituted amino, trihaloalkyl, and halogen groups.
- 14. (New) The compound of claim 3 wherein said linker moiety is substituted with at least one substituent selected from the group consisting of cyano, hydroxy, lower C₁-C₆ alkyl, lower C₁-C₆ alkoxy, nitro, amino, monosubstituted amino, trihaloalkyl, and halogen groups.